nonHDLcholesterol

NonHDLcholesterol, also known as non-HDL cholesterol or non-HDL-C, is a measure of all atherogenic lipoproteins in the blood. It is calculated by subtracting high-density lipoprotein (HDL) cholesterol from total cholesterol. Non-HDL-C thus represents the sum of LDL particles, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), lipoprotein(a), and remnant lipoproteins.

Non-HDL-C is a predictor of atherosclerotic cardiovascular disease (ASCVD) risk and is considered to reflect the total burden of atherogenic particles better than LDL-C alone in many patients, especially those with elevated triglycerides or diabetes. Because it encompasses LDL and non-LDL remnants, non-HDL-C can identify risk in individuals whose LDL-C appears near goal but who still have elevated remnant lipoproteins.

Non-HDL-C can be measured directly on a standard lipid panel and does not require fasting in most cases; it remains reliable in non-fasting samples, though very high triglycerides may affect interpretation. In practice, targets for non-HDL-C are often set about 30 mg/dL higher than the corresponding LDL-C targets, reflecting its broader scope of risk.

Management focuses on lifestyle changes and therapies that lower atherogenic lipoproteins. Statins reduce both LDL-C and non-HDL-C; additional agents such as ezetimibe, PCSK9 inhibitors, fibrates, or certain omega-3 fatty acids can further lower non-HDL-C in appropriate patients. Clinicians monitor non-HDL-C to assess treatment response, particularly when triglycerides are elevated or LDL-C measurements are difficult.